These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6234558)

  • 1. [Treatment of morning migraine. Clinical and biokinetic correlation of programmed-release dihydroergotamine].
    Aylward M; Chazot G; Maddock J; Schott B
    Presse Med; 1984 Jun; 13(26):1617-9. PubMed ID: 6234558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the treatment of migraine. Pharmacokinetic-pharmacodynamic relationships for a programmed release formulation of dihydroergotamine administered orally in the human.
    Aylward M; Davies DE; Maddock J; Robinson PR; Jones M
    Cephalalgia; 1983 Aug; 3 Suppl 1():146-50. PubMed ID: 6616596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of migraine attacks through the use of dihydroergotamine.
    Neuman M; Demarez JP; Harmey JL; Le Bastard B; Cauquil J
    Int J Clin Pharmacol Res; 1986; 6(1):11-3. PubMed ID: 3514491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ergot derivatives in the prophylaxis of migraine: a multicentric study with a timed-release dihydroergotamine formulation.
    Martucci N; Manna V; Mattesi P; Troiani G; Manzoni GC; Lanfranchi M; Bono G; Micieli G
    Cephalalgia; 1983 Aug; 3 Suppl 1():151-5. PubMed ID: 6352046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Migraine prevention with dihydroergotamine].
    Heuser B; Middendorf E
    Fortschr Med; 1985 Nov; 103(41):966-70. PubMed ID: 3905548
    [No Abstract]   [Full Text] [Related]  

  • 6. [Dihydroergotamine and flunarizine in the prevention of migraine. A comparative double-blind study].
    Langohr HD; Reinecke M; Gerber WD; Mangold R
    Fortschr Med; 1988 Jan; 106(2):65-6, 69-70. PubMed ID: 3278960
    [No Abstract]   [Full Text] [Related]  

  • 7. Dihydroergotamine nasal spray during migraine attacks. A double-blind crossover study with placebo.
    Tulunay FC; Karan O; Aydin N; Culcuoglu A; Guvener A
    Cephalalgia; 1987 Jun; 7(2):131-3. PubMed ID: 3301001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Planned release dihydroergotamine in common migraine and "tension-vascular headache": multicentre clinical trial.
    Fontanari D; Perulli L; Conte F; Tambato E; Toso V; Zanetti R
    Cephalalgia; 1983 Aug; 3 Suppl 1():189-91. PubMed ID: 6352048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A new therapeutic approach to menstrual migraine].
    Rozenbaum H
    Rev Fr Gynecol Obstet; 1984; 79(7-9):581-3. PubMed ID: 6528179
    [No Abstract]   [Full Text] [Related]  

  • 10. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.
    Aurora SK; Silberstein SD; Kori SH; Tepper SJ; Borland SW; Wang M; Dodick DW
    Headache; 2011 Apr; 51(4):507-17. PubMed ID: 21457235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators.
    Headache; 1995 Apr; 35(4):177-84. PubMed ID: 7775172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined low-dose acetylsalicylic acid and dihydroergotamine in migraine prophylaxis. A double-blind, placebo-controlled crossover study.
    Bousser MG; Chick J; Fuseau E; Soisson T; Thevenet R
    Cephalalgia; 1988 Sep; 8(3):187-92. PubMed ID: 3197098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in migraine: treatment with dihydroergotamine-retard.
    Mastrosimone F; Iaccarino C
    Cephalalgia; 1983 Aug; 3 Suppl 1():168-70. PubMed ID: 6616599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydroergotamine: role in the treatment of migraine.
    Schürks M
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1141-8. PubMed ID: 19624283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Calcium carbasalate-metoclopramide combination versus dihydroergotamine in the treatment of migraine attacks].
    Pradalier A; Guérard des Lauriers A; Scheck F; Peraudeau P; Lacoste JP; Cajfinger F
    Pathol Biol (Paris); 1995 Nov; 43(9):806-13. PubMed ID: 8746103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydroergotamine: a review of its use in the treatment of migraine and other headaches.
    Scott AK
    Clin Neuropharmacol; 1992 Aug; 15(4):289-96. PubMed ID: 1516074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repetitive intravenous dihydroergotamine as therapy for intractable migraine.
    Raskin NH
    Neurology; 1986 Jul; 36(7):995-7. PubMed ID: 3520384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timed-release dihydroergotamine in the prophylaxis of mixed headache. A study versus amitriptyline.
    Bonuso S; Di Stasio E; Barone P; Steardo L
    Cephalalgia; 1983 Aug; 3 Suppl 1():175-8. PubMed ID: 6352047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Double blind study of migraine therapy with etilefrine pivalate].
    Cruz A; Bühling M; Seibel K
    Arzneimittelforschung; 1985; 35(7):1086-9. PubMed ID: 2864937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Menstrual migraine: intermittent prophylaxis with a timed-release pharmacological formulation of dihydroergotamine.
    D'Alessandro R; Gamberini G; Lozito A; Sacquegna T
    Cephalalgia; 1983 Aug; 3 Suppl 1():156-8. PubMed ID: 6616598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.